Back to Directory
Bivalirudin
Performance & EnduranceAnticoagulant peptide used during cardiac procedures as alternative to heparin.
Key Benefits
- ✓Direct thrombin inhibition
- ✓Anticoagulation during PCI
- ✓Alternative to heparin
- ✓Predictable pharmacokinetics
- ✓Lower bleeding risk than heparin
Dosing Information
Dosage Range
0.75 mg/kg bolus
Frequency
Continuous IV during procedure
Typical Duration
Duration of procedure
Detailed Protocol
Administered via intravenous infusion during cardiac procedures. Hospital use only under close medical monitoring. Dosing based on patient weight.
About Bivalirudin
Bivalirudin (Angiomax) is a synthetic 20-amino acid peptide that directly inhibits thrombin. FDA-approved as an anticoagulant for patients undergoing percutaneous coronary intervention, including those with heparin-induced thrombocytopenia risk.
Research Notes
FDA-approved for PCI procedures. Clinical trials show efficacy comparable to heparin with potentially lower bleeding risk. Hospital use only.
Potential Side Effects
- •Bleeding risk
- •Hypotension
- •Nausea
- •Back pain
- •Requires hospital setting
Always consult with a healthcare professional before starting any peptide therapy.